Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors - PubMed (original) (raw)

Affiliations

PMID: 12374669

Clinical Trial

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors

Ramzi Dagher et al. Clin Cancer Res. 2002 Oct.

Abstract

Purpose: Imatinib mesylate (Gleevec; Novartis, East Hanover, NJ)is a receptor tyrosine kinase inhibitor approved previously in 2001 by the United States Food and Drug Administration for the treatment of chronic myelogenous leukemia in blast crisis, accelerated phase, or in chronic phase after failure of IFN-alpha therapy. We review herein the clinical profile of this drug and the regulatory review leading to the approval of a supplemental New Drug Application for the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors (GISTs).

Experimental design: We discuss the efficacy and side effects of imatinib mesylate in a Phase II trial of 147 patients with metastatic and/or unresectable malignant GISTs, the basis for marketing approval, and postmarketing commitments by the drug's manufacturer.

Results: Imatinib was assessed in a single, open-label trial involving one European center and three centers in the United States. Seventy-three patients were randomly allocated to receive 400 mg of imatinib daily, and 74 patients received 600 mg daily. At the study report cutoff date, an objective response was confirmed in 56 patients; the overall response rate for the combined study arms was 38% (95% confidence interval, 30-46%). These responses were all partial responses. There was no statistically significant difference in response rates between the two dose groups. Adverse events included edema, fluid retention, nausea, vomiting, diarrhea, myalgias, skin rash, bone marrow suppression, bleeding, and elevations in aspartate aminotransferase, alanine aminotransferase, or bilirubin. Bleeding into the gastrointestinal tract or intratumoral sites occurred in 7 patients (5%) and was not correlated with thrombocytopenia or tumor bulk. The pharmacokinetics of imatinib in GIST patients were similar to those of chronic myelogenous leukemia patients.

Conclusions: On February 1, 2001, imatinib mesylate was approved by the United States Food and Drug Administration for the treatment of malignant metastatic and/or unresectable GISTs. The recommended dose is 400 or 600 mg daily.

PubMed Disclaimer

Cited by

Effect of loss of heterozygosity of the c-kit gene on prognosis after hepatectomy for metastatic liver gastrointestinal stromal tumors.
Kikuchi H, Yamamoto M, Hiramatsu Y, Baba M, Ohta M, Kamiya K, Tanaka T, Suzuki S, Sugimura H, Kitagawa M, Kanai T, Kitayama Y, Kanda T, Nishikura K, Konno H. Kikuchi H, et al. Cancer Sci. 2007 Nov;98(11):1734-9. doi: 10.1111/j.1349-7006.2007.00592.x. Cancer Sci. 2007. PMID: 17894554 Free PMC article.
Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients.
Sammarco I, Capurso G, Coppola L, Bonifazi AP, Cassetta S, Delle Fave G, Carrara A, Grassi GB, Rossi P, Sette C, Geremia R. Sammarco I, et al. Int J Colorectal Dis. 2004 Nov;19(6):545-53. doi: 10.1007/s00384-004-0601-9. Epub 2004 May 6. Int J Colorectal Dis. 2004. PMID: 15133698
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.
Sharma SV, Haber DA, Settleman J. Sharma SV, et al. Nat Rev Cancer. 2010 Apr;10(4):241-53. doi: 10.1038/nrc2820. Epub 2010 Mar 19. Nat Rev Cancer. 2010. PMID: 20300105 Review.
Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers.
Nussinov R, Jang H, Tsai CJ, Cheng F. Nussinov R, et al. PLoS Comput Biol. 2019 Mar 28;15(3):e1006658. doi: 10.1371/journal.pcbi.1006658. eCollection 2019 Mar. PLoS Comput Biol. 2019. PMID: 30921324 Free PMC article. Review.
Imatinib for the treatment of pulmonary arterial hypertension and pulmonary capillary hemangiomatosis.
Nayyar D, Muthiah K, Kumarasinghe G, Hettiarachchi R, Celermajer D, Kotlyar E, Keogh A. Nayyar D, et al. Pulm Circ. 2014 Jun;4(2):342-5. doi: 10.1086/675996. Pulm Circ. 2014. PMID: 25006453 Free PMC article.

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors - PubMed (original) (raw)